The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Primary prophylactic granulocyte colony-stimulating factor (GCSF) in Gilbert’s disease patients treated with FOLFIRI first line for metastatic colorectal cancer (mCRC): Final results of the FFCD 0604 study.
Thierry Lecomte
Honoraria - Roche
Olivier Bouche
Consultant or Advisory Role - Pfizer; Roche
Alice oden-Gangloff
No relevant relationships to disclose
Karine Le Malicot
No relevant relationships to disclose
Thomas Aparicio
No relevant relationships to disclose
Emmanuel Mitry
Consultant or Advisory Role - Roche
Honoraria - Pfizer; Roche
Laurent Bedenne
Honoraria - Amgen
Research Funding - Chugai Pharma; Pfizer
Gael Deplanque
No relevant relationships to disclose
Julien Volet
Honoraria - Roche
David Tougeron
No relevant relationships to disclose
Franck Bonnetain
No relevant relationships to disclose
Marie Moreau
No relevant relationships to disclose
Etienne Dorval
No relevant relationships to disclose
Marie-Anne Loriot
No relevant relationships to disclose
Pierre Laurent-Puig
Honoraria - Amgen
Come Lepage
No relevant relationships to disclose